 | • レポートコード：MRC309Z7885 • 出版社/出版日：GlobalInfoResearch / 2023年9月 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| GlobalInfoResearchの最新の調査によると、世界のヒト水痘・帯状疱疹免疫グロブリンの市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。 このレポートは、世界のヒト水痘・帯状疱疹免疫グロブリン市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。 市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。 本レポートの主な目的は次のとおりです。 - 世界および主要国の市場機会の規模を決定するため - ヒト水痘・帯状疱疹免疫グロブリンの成長可能性を評価するため - 各製品および最終用途市場の将来の成長を予測するため - 市場に影響を与える競争要因を評価するため ヒト水痘・帯状疱疹免疫グロブリン市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメント ・フリーズドライ粉末、注射剤 用途別セグメント ・病院、診療所 主要な市場プレーヤー ・Bio Products Laboratory、MassBiologics、Saol Therapeutics、Aptevo Biotherapeutics Llc、Ki Biopharma Llc、Cangene Biopharma、Kamada、Salmedon 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、ヒト水痘・帯状疱疹免疫グロブリン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なヒト水痘・帯状疱疹免疫グロブリンメーカーの企業概要、2019年～2022年までのヒト水痘・帯状疱疹免疫グロブリンの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なヒト水痘・帯状疱疹免疫グロブリンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2018年～2029年までの地域別ヒト水痘・帯状疱疹免疫グロブリンの販売量、売上、成長性を示しています。 ・第5、6章では、2018年～2029年までのヒト水痘・帯状疱疹免疫グロブリンの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域でのヒト水痘・帯状疱疹免疫グロブリン市場予測を収録しています。 ・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。 ・第13章では、主要な原材料、主要なサプライヤー、およびヒト水痘・帯状疱疹免疫グロブリンの産業チェーンを掲載しています。 ・第14、15章では、ヒト水痘・帯状疱疹免疫グロブリンの販売チャネル、販売業者、顧客、調査結果について説明します。 ***** 目次(一部) ***** ・市場概要 - ヒト水痘・帯状疱疹免疫グロブリンの概要 - 種類別分析（2018年vs2022年vs2029年）：フリーズドライ粉末、注射剤 - 用途別分析（2018年vs2022年vs2029年）：病院、診療所 - 世界のヒト水痘・帯状疱疹免疫グロブリン市場規模・予測 - 世界のヒト水痘・帯状疱疹免疫グロブリン生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Bio Products Laboratory、MassBiologics、Saol Therapeutics、Aptevo Biotherapeutics Llc、Ki Biopharma Llc、Cangene Biopharma、Kamada、Salmedon ・メーカー別市場シェア・市場集中度 ・地域別市場分析2018年-2029年 ・種類別分析2018年-2029年：フリーズドライ粉末、注射剤 ・用途別分析2018年-2029年：病院、診療所 ・ヒト水痘・帯状疱疹免疫グロブリンの北米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・ヒト水痘・帯状疱疹免疫グロブリンのヨーロッパ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・ヒト水痘・帯状疱疹免疫グロブリンのアジア市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・ヒト水痘・帯状疱疹免疫グロブリンの南米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・ヒト水痘・帯状疱疹免疫グロブリンの中東・アフリカ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析） ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
According to our (Global Info Research) latest study, the global Human Varicella-Zoster Immunoglobulin market size was valued at USD 163.6 million in 2022 and is forecast to a readjusted size of USD 204 million by 2029 with a CAGR of 3.2% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Herpes zoster is an acute herpetic viral skin disease caused by the varicella-zoster virus that involves the nerves and skin. Infected individuals treated with human water were less likely to develop severe varicella-zoster virus than those not treated with it.
Human varicella-zoster immune globulin is a solution of antibodies used for post exposure prophylaxis of varicella infections in high risk populations, as well as to reduce the severity of infections.
This report is a detailed and comprehensive analysis for global Human Varicella-Zoster Immunoglobulin market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Human Varicella-Zoster Immunoglobulin market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Human Varicella-Zoster Immunoglobulin market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Human Varicella-Zoster Immunoglobulin market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Human Varicella-Zoster Immunoglobulin market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Human Varicella-Zoster Immunoglobulin
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Human Varicella-Zoster Immunoglobulin market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bio Products Laboratory, MassBiologics, Saol Therapeutics, Aptevo Biotherapeutics Llc and Ki Biopharma Llc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Human Varicella-Zoster Immunoglobulin market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Freeze-dried Powder
Injection
Market segment by Application
Hospital
Clinic
Major players covered
Bio Products Laboratory
MassBiologics
Saol Therapeutics
Aptevo Biotherapeutics Llc
Ki Biopharma Llc
Cangene Biopharma
Kamada
Salmedon
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human Varicella-Zoster Immunoglobulin product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Human Varicella-Zoster Immunoglobulin, with price, sales, revenue and global market share of Human Varicella-Zoster Immunoglobulin from 2018 to 2023.
Chapter 3, the Human Varicella-Zoster Immunoglobulin competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Varicella-Zoster Immunoglobulin breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Human Varicella-Zoster Immunoglobulin market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Human Varicella-Zoster Immunoglobulin.
Chapter 14 and 15, to describe Human Varicella-Zoster Immunoglobulin sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Human Varicella-Zoster Immunoglobulin
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Human Varicella-Zoster Immunoglobulin Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Freeze-dried Powder
1.3.3 Injection
1.4 Market Analysis by Application
1.4.1 Overview: Global Human Varicella-Zoster Immunoglobulin Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.5 Global Human Varicella-Zoster Immunoglobulin Market Size & Forecast
1.5.1 Global Human Varicella-Zoster Immunoglobulin Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Human Varicella-Zoster Immunoglobulin Sales Quantity (2018-2029)
1.5.3 Global Human Varicella-Zoster Immunoglobulin Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Bio Products Laboratory
2.1.1 Bio Products Laboratory Details
2.1.2 Bio Products Laboratory Major Business
2.1.3 Bio Products Laboratory Human Varicella-Zoster Immunoglobulin Product and Services
2.1.4 Bio Products Laboratory Human Varicella-Zoster Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bio Products Laboratory Recent Developments/Updates
2.2 MassBiologics
2.2.1 MassBiologics Details
2.2.2 MassBiologics Major Business
2.2.3 MassBiologics Human Varicella-Zoster Immunoglobulin Product and Services
2.2.4 MassBiologics Human Varicella-Zoster Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 MassBiologics Recent Developments/Updates
2.3 Saol Therapeutics
2.3.1 Saol Therapeutics Details
2.3.2 Saol Therapeutics Major Business
2.3.3 Saol Therapeutics Human Varicella-Zoster Immunoglobulin Product and Services
2.3.4 Saol Therapeutics Human Varicella-Zoster Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Saol Therapeutics Recent Developments/Updates
2.4 Aptevo Biotherapeutics Llc
2.4.1 Aptevo Biotherapeutics Llc Details
2.4.2 Aptevo Biotherapeutics Llc Major Business
2.4.3 Aptevo Biotherapeutics Llc Human Varicella-Zoster Immunoglobulin Product and Services
2.4.4 Aptevo Biotherapeutics Llc Human Varicella-Zoster Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Aptevo Biotherapeutics Llc Recent Developments/Updates
2.5 Ki Biopharma Llc
2.5.1 Ki Biopharma Llc Details
2.5.2 Ki Biopharma Llc Major Business
2.5.3 Ki Biopharma Llc Human Varicella-Zoster Immunoglobulin Product and Services
2.5.4 Ki Biopharma Llc Human Varicella-Zoster Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Ki Biopharma Llc Recent Developments/Updates
2.6 Cangene Biopharma
2.6.1 Cangene Biopharma Details
2.6.2 Cangene Biopharma Major Business
2.6.3 Cangene Biopharma Human Varicella-Zoster Immunoglobulin Product and Services
2.6.4 Cangene Biopharma Human Varicella-Zoster Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Cangene Biopharma Recent Developments/Updates
2.7 Kamada
2.7.1 Kamada Details
2.7.2 Kamada Major Business
2.7.3 Kamada Human Varicella-Zoster Immunoglobulin Product and Services
2.7.4 Kamada Human Varicella-Zoster Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Kamada Recent Developments/Updates
2.8 Salmedon
2.8.1 Salmedon Details
2.8.2 Salmedon Major Business
2.8.3 Salmedon Human Varicella-Zoster Immunoglobulin Product and Services
2.8.4 Salmedon Human Varicella-Zoster Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Salmedon Recent Developments/Updates
3 Competitive Environment: Human Varicella-Zoster Immunoglobulin by Manufacturer
3.1 Global Human Varicella-Zoster Immunoglobulin Sales Quantity by Manufacturer (2018-2023)
3.2 Global Human Varicella-Zoster Immunoglobulin Revenue by Manufacturer (2018-2023)
3.3 Global Human Varicella-Zoster Immunoglobulin Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Human Varicella-Zoster Immunoglobulin by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Human Varicella-Zoster Immunoglobulin Manufacturer Market Share in 2022
3.4.2 Top 6 Human Varicella-Zoster Immunoglobulin Manufacturer Market Share in 2022
3.5 Human Varicella-Zoster Immunoglobulin Market: Overall Company Footprint Analysis
3.5.1 Human Varicella-Zoster Immunoglobulin Market: Region Footprint
3.5.2 Human Varicella-Zoster Immunoglobulin Market: Company Product Type Footprint
3.5.3 Human Varicella-Zoster Immunoglobulin Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Human Varicella-Zoster Immunoglobulin Market Size by Region
4.1.1 Global Human Varicella-Zoster Immunoglobulin Sales Quantity by Region (2018-2029)
4.1.2 Global Human Varicella-Zoster Immunoglobulin Consumption Value by Region (2018-2029)
4.1.3 Global Human Varicella-Zoster Immunoglobulin Average Price by Region (2018-2029)
4.2 North America Human Varicella-Zoster Immunoglobulin Consumption Value (2018-2029)
4.3 Europe Human Varicella-Zoster Immunoglobulin Consumption Value (2018-2029)
4.4 Asia-Pacific Human Varicella-Zoster Immunoglobulin Consumption Value (2018-2029)
4.5 South America Human Varicella-Zoster Immunoglobulin Consumption Value (2018-2029)
4.6 Middle East and Africa Human Varicella-Zoster Immunoglobulin Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Human Varicella-Zoster Immunoglobulin Sales Quantity by Type (2018-2029)
5.2 Global Human Varicella-Zoster Immunoglobulin Consumption Value by Type (2018-2029)
5.3 Global Human Varicella-Zoster Immunoglobulin Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Human Varicella-Zoster Immunoglobulin Sales Quantity by Application (2018-2029)
6.2 Global Human Varicella-Zoster Immunoglobulin Consumption Value by Application (2018-2029)
6.3 Global Human Varicella-Zoster Immunoglobulin Average Price by Application (2018-2029)
7 North America
7.1 North America Human Varicella-Zoster Immunoglobulin Sales Quantity by Type (2018-2029)
7.2 North America Human Varicella-Zoster Immunoglobulin Sales Quantity by Application (2018-2029)
7.3 North America Human Varicella-Zoster Immunoglobulin Market Size by Country
7.3.1 North America Human Varicella-Zoster Immunoglobulin Sales Quantity by Country (2018-2029)
7.3.2 North America Human Varicella-Zoster Immunoglobulin Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Human Varicella-Zoster Immunoglobulin Sales Quantity by Type (2018-2029)
8.2 Europe Human Varicella-Zoster Immunoglobulin Sales Quantity by Application (2018-2029)
8.3 Europe Human Varicella-Zoster Immunoglobulin Market Size by Country
8.3.1 Europe Human Varicella-Zoster Immunoglobulin Sales Quantity by Country (2018-2029)
8.3.2 Europe Human Varicella-Zoster Immunoglobulin Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Human Varicella-Zoster Immunoglobulin Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Human Varicella-Zoster Immunoglobulin Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Human Varicella-Zoster Immunoglobulin Market Size by Region
9.3.1 Asia-Pacific Human Varicella-Zoster Immunoglobulin Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Human Varicella-Zoster Immunoglobulin Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Human Varicella-Zoster Immunoglobulin Sales Quantity by Type (2018-2029)
10.2 South America Human Varicella-Zoster Immunoglobulin Sales Quantity by Application (2018-2029)
10.3 South America Human Varicella-Zoster Immunoglobulin Market Size by Country
10.3.1 South America Human Varicella-Zoster Immunoglobulin Sales Quantity by Country (2018-2029)
10.3.2 South America Human Varicella-Zoster Immunoglobulin Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Human Varicella-Zoster Immunoglobulin Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Human Varicella-Zoster Immunoglobulin Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Human Varicella-Zoster Immunoglobulin Market Size by Country
11.3.1 Middle East & Africa Human Varicella-Zoster Immunoglobulin Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Human Varicella-Zoster Immunoglobulin Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Human Varicella-Zoster Immunoglobulin Market Drivers
12.2 Human Varicella-Zoster Immunoglobulin Market Restraints
12.3 Human Varicella-Zoster Immunoglobulin Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Human Varicella-Zoster Immunoglobulin and Key Manufacturers
13.2 Manufacturing Costs Percentage of Human Varicella-Zoster Immunoglobulin
13.3 Human Varicella-Zoster Immunoglobulin Production Process
13.4 Human Varicella-Zoster Immunoglobulin Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Human Varicella-Zoster Immunoglobulin Typical Distributors
14.3 Human Varicella-Zoster Immunoglobulin Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer